COMMUNIQUÉS West-GlobeNewswire

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
23/04/2026
Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction [...]
IMAAVY® (nipocalimab)▼shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)
23/04/2026
Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving sustained [...]
Chiffre d'affaires du 1er trimestre 2026
23/04/2026
Communiqué de presse Le chiffre d’affaires au 31 mars 2026 s’établit à €1 336m , en progression de +4,9% en base organique par rapport au 1 er trimestre 2025 L’ensemble des activités et des régions contribue à la [...]
First-quarter 2026 revenue
23/04/2026
Press release Revenue as at 31 March 2026 stood at €1 , 336m , up +4.9% on an organic basis compared with the first quarter of 2025 All business segments and regions contributed to revenue growth, supported by [...]
PridCor Therapeutics Secures Global Antiviral Portfolio, Establishing Leadership in Treatment of Long COVID and Infection-Associated Chronic Illnesses
23/04/2026
TUSCALOOSA, Ala., April 23, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics LLC, a clinical-stage biopharmaceutical company, today announced the acquisition of a global antiviral asset portfolio, establishing the Company [...]
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
23/04/2026
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mars 2026
23/04/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation
23/04/2026
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
Ritedose, University of South Carolina Welcome Top European Business Students for Immersive Learning about Advanced Manufacturing
23/04/2026
Collaboration showcases the Ritedose Center of Excellence as a global hub for advanced manufacturing education. The Center of Excellence serves as a cornerstone of Ritedose’s broader commitment to workforce development [...]
Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling
23/04/2026
Tilray Medical Poised to Accelerate U.S. Medical Cannabis Access for Patients NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.  (“Tilray”, “our”, “we” or the “Company”) (NASDAQ: TLRY; TSX: TLRY), a [...]
Codexis to Report First Quarter 2026 Financial Results on May 7
23/04/2026
REDWOOD CITY, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it [...]
NEW YORK PLASTIC SURGICAL GROUP ANNOUNCES OPENING OF HARRISON, NY LOCATION
23/04/2026
Harrison, NY, April 23, 2026 (GLOBE NEWSWIRE) -- New York Plastic Surgical Group (NYPS Group), one of the nation’s longest‑standing and most respected private academic plastic surgery practices, is proud to announce the [...]
MAPS Celebrates 40 Years at a Defining Moment for Psychedelics
23/04/2026
Founded in April 1986 to advance psychedelic research and knowledge, MAPS has raised more than $150 million, supported 45 studies, and shaped the global policy and cultural landscape of psychedelics. As science, policy [...]
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
23/04/2026
Expect to report topline data from both studies mid-2026 SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage [...]
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
23/04/2026
- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royalty up to 15% on Net [...]
Neocis and Yomi® S Named Winner of the 2026 TAG Awards for MedTech in Robotic & Procedural Innovation
23/04/2026
MIAMI, April 23, 2026 (GLOBE NEWSWIRE) -- Neocis®, the company behind the first and only FDA-cleared robotic system for dental implant surgery, today announced that Yomi® S has been named a winner of the 2026 TAG Awards [...]
H1 Launches Site Network Suite, the First AI-Powered Platform to Transform How Research Sites and Sponsors Engage on Clinical Trials
23/04/2026
H1’s Core AI Engine Helps Sponsors Find Sites More Efficiently and Determine Feasibility Faster, Bringing Process from Months to Weeks NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- H1 , the AI-powered platform that [...]
Jushi Holdings Inc. Applauds President Trump and Administration for Delivering on Cannabis Rescheduling to Schedule III under the Controlled Substances Act
23/04/2026
BOCA RATON, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) (OTCQX: JUSHF ) , a vertically integrated, multi-state cannabis operator, applauds President Donald J. [...]
InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
23/04/2026
BEIJING, April 23, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced its results and business highlights for the first quarter of 2026 as of 31 March 2026. Over the past decade, [...]

Pages